Welcome to AstraZeneca United States

绿贝加速器


绿贝加速器


Researching antibodies to target COVID-19

AstraZeneca is joining forces with government and academia with the aim of discovering novel coronavirus-neutralising antibodies. Harnessing internal expertise and via new collaborations, the aim is to identify monoclonal antibodies that have the potential to recognise, bind to and neutralise the SARS-CoV-2 virus, to decrease the impact of COVID-19.


绿贝加速器